A Single-centre retrospective observational study to assessed the efficacy and tolerability of switching from bimatoprost 0.01% to 0.03% in a patient with various types of glaucoma in a real-world clinical setting
Latest Information Update: 06 Dec 2022
At a glance
- Drugs Bimatoprost (Primary)
- Indications Angle-closure glaucoma; Low tension glaucoma; Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- 06 Dec 2022 New trial record